Sunwoda Joins 2026 Sungrow Global Partners Conference to Deepen Global Collaboration and Sustainability

Sunwoda Joins 2026 Sungrow Global Partners Conference to Deepen Global Collaboration and Sustainability

HEFEI, China, Jan. 8, 2026 /PRNewswire/ -- On January 8, Sunwoda, as a global partner of Sungrow, attended the 2026 Sungrow Global Partners Conference in Hefei, Anhui Province, to discuss international expansion and sustainable development. Wang...

Kolmar Korea Wins CES 2026 Best of Innovation Award in Beauty Tech, a Global First for the Cosmetics Industry

Kolmar Korea Wins CES 2026 Best of Innovation Award in Beauty Tech, a Global First for the Cosmetics Industry

Proving global competitiveness in beauty tech by capturing the CES "Best of Innovation Award" AI-powered 'Scar Beauty Device' earns double honors in Beauty Tech and Digital Health categories LAS VEGAS, Jan. 7, 2026 /PRNewswire/ -- Kolmar Korea...

Dreame Debuts Revolutionary Hair Care Lineup at CES 2026: AI-Powered Pilot 20 Hair Dryer Features Dual Robotic Arms for Proactive Care

Dreame Debuts Revolutionary Hair Care Lineup at CES 2026: AI-Powered Pilot 20 Hair Dryer Features Dual Robotic Arms for Proactive Care

LAS VEGAS, Jan. 7, 2026 /PRNewswire/ -- Dreame Technology, a global leader in high-end consumer electronics and intelligent manufacturing, today unveiled a series of smart beauty products redefining the future of personal care at CES 2026. The...

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and...

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

- The P hase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the...

GAC Receives Industry's First Vehicle Data Security Management System Certificate

GAC Receives Industry's First Vehicle Data Security Management System Certificate

TIANJIN, China and GUANGZHOU, China, Dec. 31, 2025 /PRNewswire/ -- On December 24th, GAC received renewed authoritative recognition in vehicle data security by obtaining the industry's first Vehicle Data Security Management System Certification...

WF International Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

WF International Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

CHENGDU, China, Dec. 31, 2025 /PRNewswire/ -- WF International Limited (the "Company" or "WF International") (NASDAQ: WXM), an integrated electromechanical solutions company specializing in the supply, installation, fitting-out, and maintenance of...

China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval

China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR)...

FP Markets Celebrates 20 Years of Transforming Trading and Looks Ahead to a New Era of Growth

FP Markets Celebrates 20 Years of Transforming Trading and Looks Ahead to a New Era of Growth

SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Global multi-asset broker FP Markets proudly marked its twentieth anniversary this year, celebrating two decades of 'Transforming Trading' through innovation, performance-driven technology, and a commitment to...

Cloopen Announces Receipt of Preliminary Non-Binding "Going Private" Proposal

Cloopen Announces Receipt of Preliminary Non-Binding "Going Private" Proposal

BEIJING, Dec. 24, 2025 /PRNewswire/ -- Cloopen Group Holding Limited (OTC: RAASY) ("Cloopen" or the "Company") today announced that its Board of Directors (the "Board") has received a preliminary non-binding proposal letter (the "Proposal"), dated...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 17
  • menu
    menu